Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
iodoxamic acid
- Development stage
- Unknown
- Lead developer
- Bracco
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Iodoxamic acid is a hexaiodinated, water-soluble radiographic contrast medium specifically developed for intravenous cholangiography and cholecystography. It is used to visualize the biliary tree and gallbladder during diagnostic imaging procedures, such as CT cholangiography. The drug is primarily eliminated via biliary excretion, where it achieves high concentrations in the bile to provide radiopacity. Developed by Bracco, it was marketed under brand names like Endomirabil and Endobil. While it was a standard agent for biliary imaging in the late 20th century, its use has largely been superseded by non-invasive modalities like magnetic resonance cholangiopancreatography (MRCP) and ultrasound.
- Brand names
- EndomirabilEndobil
- Other names
- iodoxamatemeglumine iodoxamateiodoxamic acid meglumine
Beyond the preview
Go deeper on iodoxamic acid.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on iodoxamic acid.